These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18682513)

  • 41. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.
    Bogazzi F; Manetti L; Raffaelli V; Lombardi M; Rossi G; Martino E
    J Endocrinol Invest; 2008 Dec; 31(12):1119-23. PubMed ID: 19246980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma.
    Hayes AG; Shirazi MG; Thiyagarajah A; Torpy DJ; De Sousa SMC
    Endocr Oncol; 2023 Jan; 3(1):e220086. PubMed ID: 37434646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.
    Gürbüz F; Yağcı-Küpeli B; Kör Y; Yüksel B; Zorludemir S; Gürbüz BB; Küpeli S
    J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):159-63. PubMed ID: 23945126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
    Melis GB; Gambacciani M; Paoletti AM; Mais V; Sghedoni D; Fioretti P
    Fertil Steril; 1989 Sep; 52(3):412-5. PubMed ID: 2570719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.
    Khare S; Lila AR; Patil R; Phadke M; Kerkar P; Bandgar T; Shah NS
    Indian J Endocrinol Metab; 2017; 21(1):154-159. PubMed ID: 28217516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The frequency of cardiac valvular regurgitation in Parkinson's disease.
    Yamashiro K; Komine-Kobayashi M; Hatano T; Urabe T; Mochizuki H; Hattori N; Iwama Y; Daida H; Sakai M; Nakayama T; Mizuno Y
    Mov Disord; 2008 May; 23(7):935-941. PubMed ID: 18398916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
    Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prevalence and clinical significance of tricuspid valve regurgitation in normally grown fetuses and those with intrauterine growth retardation.
    Gembruch U; Smrcek JM
    Ultrasound Obstet Gynecol; 1997 Jun; 9(6):374-82. PubMed ID: 9239822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
    Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
    De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
    Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
    Castro-Castro J; Torre-Eiriz JA; Pinzón-Millán A; Pastor-Zapata A
    Neurocirugia (Astur); 2011 Dec; 22(6):558-61; discussion 561. PubMed ID: 22167286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison between the heart of young athletes and of young healthy sedentary subjects: a morphometric and morpho-functional study by echo-color-doppler method.
    Macchi C; Catini C; Catini CR; Contini M; Zito A; Urbano F; Miniati B; Molino Lova R; Gulisano M; Brizzi E
    Ital J Anat Embryol; 2001; 106(3):221-31. PubMed ID: 11767198
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole.
    Springer C; Rodgers R; Vivino G; Attanagoda S; Miks CD
    Clin Neuropharmacol; 2023 May-Jun 01; 46(3):126-127. PubMed ID: 37191567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
    Lebbe M; Hubinont C; Bernard P; Maiter D
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
    Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
    J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dexfenfluramine and heart-valve regurgitation in Chinese patients with type 2 diabetes.
    Ko GT; Chan HC; Chow CC
    Hong Kong Med J; 2003 Aug; 9(4):243-6. PubMed ID: 12904610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and risk factors of tricuspid regurgitation after correction of tetralogy of Fallot.
    Kobayashi J; Kawashima Y; Matsuda H; Nakano S; Miura T; Tokuan Y; Arisawa J
    J Thorac Cardiovasc Surg; 1991 Oct; 102(4):611-6. PubMed ID: 1921437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.